Roth Capital Predicts Weaker Earnings for Zevra Therapeutics

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Analysts at Roth Capital dropped their FY2029 EPS estimates for shares of Zevra Therapeutics in a report issued on Tuesday, March 11th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings of $2.05 per share for the year, down from their previous estimate of $2.26. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share.

Several other research analysts have also weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research note on Thursday. Guggenheim boosted their price objective on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday. Canaccord Genuity Group boosted their price objective on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $22.14.

Zevra Therapeutics Stock Up 0.3 %

Shares of ZVRA stock opened at $7.94 on Thursday. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.76. The firm’s fifty day moving average price is $7.93 and its two-hundred day moving average price is $8.14. The firm has a market capitalization of $423.81 million, a P/E ratio of -4.03 and a beta of 1.98.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.28). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The business had revenue of $12.00 million during the quarter, compared to analyst estimates of $8.93 million.

Insider Activity at Zevra Therapeutics

In other Zevra Therapeutics news, CEO Neil F. Mcfarlane sold 61,273 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $481,605.78. Following the completion of the sale, the chief executive officer now owns 222,060 shares of the company’s stock, valued at $1,745,391.60. The trade was a 21.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO R. Laduane Clifton sold 11,000 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the completion of the sale, the chief financial officer now directly owns 51,361 shares of the company’s stock, valued at $403,697.46. This represents a 17.64 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 85,773 shares of company stock worth $674,176. Insiders own 2.40% of the company’s stock.

Institutional Trading of Zevra Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Woodline Partners LP boosted its holdings in Zevra Therapeutics by 2.2% in the 4th quarter. Woodline Partners LP now owns 4,139,593 shares of the company’s stock valued at $34,524,000 after purchasing an additional 90,940 shares during the period. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Zevra Therapeutics by 462.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company’s stock worth $30,441,000 after acquiring an additional 3,001,000 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Zevra Therapeutics by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 2,824,212 shares of the company’s stock worth $23,554,000 after acquiring an additional 68,151 shares during the period. FMR LLC lifted its holdings in shares of Zevra Therapeutics by 282,687.5% during the 3rd quarter. FMR LLC now owns 2,313,202 shares of the company’s stock worth $16,054,000 after acquiring an additional 2,312,384 shares during the period. Finally, Altium Capital Management LLC lifted its holdings in shares of Zevra Therapeutics by 8.8% during the 4th quarter. Altium Capital Management LLC now owns 1,850,000 shares of the company’s stock worth $15,429,000 after acquiring an additional 150,000 shares during the period. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.